Roche Holding AG (RHHVF)
OTCMKTS · Delayed Price · Currency is USD
462.16
-4.12 (-0.88%)
Feb 13, 2026, 3:48 PM EST
Roche Holding AG Revenue
In the year 2025, Roche Holding AG had annual revenue of 63.36B CHF with 1.54% growth. Roche Holding AG had revenue of 31.51B in the half year ending December 31, 2025, with 5.64% growth.
Revenue
63.36B CHF
Revenue Growth
+1.54%
P/S Ratio
4.70
Revenue / Employee
613.62K CHF
Employees
103,249
Market Cap
375.15B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63.36B | 961.00M | 1.54% |
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Stem Cell Authority | 3.33M |
| Northwest Biotherapeutics | 937.00K |
Roche Holding AG News
- 22 hours ago - Genentech Reports Positive Phase III Results For Gazyva In Primary Membranous Nephropathy - Nasdaq
- 22 hours ago - Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease - GlobeNewsWire
- 22 hours ago - Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease - Business Wire
- 6 days ago - Roche Holding AG (RHHBY) Shareholder/Analyst Presentation - Seeking Alpha
- 7 days ago - Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript - Seeking Alpha
- 7 days ago - Roche Says Experimental Drug Helped Slow Disability In Progressive Multiple Sclerosis Study - Benzinga
- 9 days ago - Roche's (RHHBY) Fenebrutinib Shows Promise in Phase 3 MS Trial - GuruFocus
- 9 days ago - Roche's multiple sclerosis drug fenebrutinib meets goal in late-stage trial - Reuters